论文部分内容阅读
目的:分析曲美他嗪对缺血性心肌病患者血浆C反应蛋白(CRP)水平和心功能的影响。方法:缺血性心肌病患者60例,随机分为对照组(常规药物治疗)和治疗组(常规药物加曲美他嗪治疗),每组各30例,全部入选患者于观察起点及用药3个月时行6 min步行试验(6MWD)、心脏彩色超声检查及测定血浆CRP浓度,比较各组患者心功能改善情况及血浆CRP的变化。结果:两组患者治疗前后自身比较,6MWD、左室射血分数均增加,血浆CRP水平均有下降,而治疗组明显优于对照组,差异有统计学意义(P<0.05),治疗组治疗后二尖瓣舒张早期血流速度峰值/二类瓣舒张晚期血流速度峰值的比值(E/A)较前明显升高(P<0.05),而对照组无明显变化(P>0.05)。结论:在常规治疗的基础上加用曲美他嗪能改善缺血性心肌病患者的心脏收缩及舒张功能,同时能显著降低血浆CRP的水平,改善患者预后。
Objective: To analyze the effect of trimetazidine on plasma C-reactive protein (CRP) level and cardiac function in patients with ischemic cardiomyopathy. Methods: 60 patients with ischemic cardiomyopathy were randomly divided into control group (conventional drug treatment) and treatment group (conventional drug plus trimetazidine treatment), 30 cases in each group, all selected patients in the observation of starting point and medication 3 6-month walking test (6MWD), color ultrasound examination of heart and determination of plasma CRP concentration were performed in months. The changes of cardiac function and plasma CRP in each group were compared. Results: Before and after treatment, the levels of 6MWD and left ventricular ejection fraction increased and plasma CRP levels decreased in both groups, but the treatment group was significantly better than the control group (P <0.05). The treatment group The ratio of peak early mitral diastolic velocity / peak diastolic velocity was higher than before (P <0.05), but there was no significant change in control group (P> 0.05). CONCLUSION: Trimetazidine can improve cardiac contractility and diastolic function in patients with ischemic cardiomyopathy on the basis of routine treatment, meanwhile, it can significantly reduce the level of plasma CRP and improve the prognosis of patients.